Nurix (NASDAQ: NRIX) Chief Legal Officer sells 3,760 shares after option exercise

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. insider activity: Chief Legal Officer Christine Ring reported option exercises and share sales in Nurix Therapeutics, Inc. common stock. On 01/20/2026, she exercised 3,760 employee stock options at an exercise price of $1.86 per share, acquiring 3,760 shares of common stock. That same day, she sold 3,760 shares of common stock at a weighted average price of $18.4237 per share under a previously adopted Rule 10b5-1 trading plan. After these transactions, she beneficially owned 50,897 shares of common stock directly and 8,643 stock options.

Insider Trade Summary

Net Seller: 3,760 shares ($69,273)

Net Sell 3 txns

Insider Ring Christine

Role Chief Legal Officer

Sold 3,760 shs ($69K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	3,760	$0.00	--
Exercise	Common Stock	3,760	$1.86	$7K
Sale	Common Stock	3,760	$18.4237	$69K

Holdings After Transaction: Employee Stock Option (right to buy) — 8,643 shares (Direct); Common Stock — 54,657 shares (Direct)

Footnotes (1)

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $18.18 and the highest price at which shares were sold was $18.69. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ring Christine

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		M(1)		3,760	A	$1.86	54,657	D
Common Stock	01/20/2026		S(1)		3,760	D	$18.4237(2)	50,897	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.86	01/20/2026		M			3,760	(3)	09/30/2029	Common Stock	3,760	$0	8,643	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $18.18 and the highest price at which shares were sold was $18.69. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nurix Therapeutics (NRIX) report for Christine Ring?

Nurix Therapeutics (NRIX) reported that Chief Legal Officer Christine Ring exercised 3,760 employee stock options and sold 3,760 shares of common stock on 01/20/2026.

At what prices did Christine Ring exercise and sell NRIX shares?

She exercised employee stock options at an exercise price of $1.86 per share and sold 3,760 shares of Nurix common stock at a weighted average price of $18.4237 per share, with individual sale prices ranging from $18.18 to $18.69.

How many Nurix (NRIX) shares does Christine Ring own after this Form 4 transaction?

Following the reported transactions, Christine Ring beneficially owned 50,897 shares of Nurix common stock directly.

How many Nurix stock options does Christine Ring hold after the reported transaction?

After the option exercise on 01/20/2026, she held 8,643 employee stock options (right to buy) directly.

Was the NRIX insider sale by Christine Ring under a Rule 10b5-1 trading plan?

Yes. The filing states that the transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

What was the vesting schedule for the Nurix stock options exercised by Christine Ring?

The option vested as to 1/4 of the total shares on September 9, 2020, and 1/48 of the total shares vested monthly thereafter until fully vested on August 9, 2023.